| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6355656 | SANDOZ | Phenidate drug formulations having diminished abuse potential |
Dec, 2015
(8 years ago) | |
| US6528530 | SANDOZ | Phenidate drug formulations having diminished abuse potential |
Dec, 2015
(8 years ago) | |
| US5908850 | SANDOZ | Method of treating attention deficit disorders with d-threo methylphenidate |
Dec, 2015
(8 years ago) | |
Focalin is owned by Sandoz.
Focalin contains Dexmethylphenidate Hydrochloride.
Focalin has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Focalin are:
- US6355656
- US6528530
- US5908850
Focalin was authorised for market use on 13 November, 2001.
Focalin is available in tablet;oral dosage forms.
Focalin can be used as method of treating at least one of attention deficit disorder and attention deficit hyperactivity disorder.
The generics of Focalin are possible to be released after 04 December, 2015.
Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 November, 2001
Treatment: Method of treating at least one of attention deficit disorder and attention deficit hyperactivity disorder
Dosage: TABLET;ORAL
FOCALIN family patents
